Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN PF 7 versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN PF 7 versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN-PF 7% vs TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-PF 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth in parenteral nutrition.
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids, electrolytes, and calories (as dextrose). Amino acids are used for protein synthesis, and electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion; typical adult dose: 1-2 g amino acids/kg/day (e.g., 14-28 mL/kg/day for 7% solution) as part of parenteral nutrition. Infusion rate not to exceed 0.1 g amino acids/kg/hour.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour, adjusted to meet metabolic needs. Typical adult daily dose: 0.8-1.5 g amino acids/kg/day, equivalent to 23-43 mL/kg/day of TRAVASOL 3.5%.
None Documented
None Documented
As a mixture of amino acids, individual amino acids have half-lives ranging from minutes to hours; clinically, continuous infusion maintains steady state.
Not applicable as a fixed half-life; amino acids have rapid plasma clearance (t1/2 of 10-30 minutes for individual amino acids). Clinical context: Continuous infusion maintains steady state.
Amino acids are primarily cleared by metabolism; less than 10% is excreted unchanged in urine.
Renal: >95% of infused amino acids and electrolytes are excreted unchanged or as metabolites. Biliary/fecal: <5%.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution